BofA raised the firm’s price target on Concentra (CON) to $25 from $24 and keeps a Buy rating on the shares after the company announced an agreement to acquire Nova Medical Centers for $265M, pre-announced Q4 results, and provided 2025 guide that was roughly in line with consensus excluding the Nova deal contribution. The firm raised its estimates for a better Q4 and the deal and raised its multiple given the increased visibility into estimates.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON: